Exploring the Innovative Feeder-Free IL-2-Independent TIL Process by Juncell Therapeutics at ASGCT 2025
Juncell Therapeutics Unveils Groundbreaking IL-2-Independent TIL Manufacturing Process
On April 28, 2025, Shanghai Juncell Therapeutics Co., Ltd. announced its pivotal findings regarding a new manufacturing process for Tumor-Infiltrating Lymphocytes (TILs) that operates without interleukin-2 (IL-2). This significant advancement will be presented at the upcoming 28th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT), scheduled for May 13–15, 2025, in New Orleans, Louisiana.
Breakthroughs in TIL Technology
Juncell Therapeutics has been at the forefront of developing advanced TIL therapies aimed at treating various types of solid tumors. The company’s innovative research has led to a feeder-free system that facilitates the generation of functional TILs from both
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.